Vertex Pharmaceuticals

Biotechnology
VRTX
$ 312 (1.7)%
Share price
$ 80 bn
Market Cap
$ 74 bn
Enterprise Value

Carbon footprint

0.18 Ton
GHG emissions per $ 1 mln investment
0x the weighted average for S&P 500
FY2021
How is this calculated?
-1.2%
YOY change in GHG emissions
Weaker than the +4.2% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-0.2%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

Vertex Pharmaceuticals aims to reduce Scope 1 + 2 by 20% by 2023 from a base year 2018

This target is most likely outdated and the company appears to have already achieved it
This target has not been verified as science based according to SBTi
Vertex Pharmaceuticals's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Vertex Pharmaceuticals's GHG emissions (market-based) (Kt of CO2e)
Vertex Pharmaceuticals's Carbon intensity (Tons per 1 USDm)

Vertex Pharmaceuticals's carbon footprint

Vertex Pharmaceuticals reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 13 Kt (-0.16 /-1.2% y-o-y). Also positively, carbon intensity decreased to 1.8 t (-0.4 /-18.2% y-o-y).

No public disclosure of Scope 3 emissions has been found for Vertex Pharmaceuticals at the moment.

The company is committed to reducing Scope 1 + 2 by 20% by 2023 from a base year 2018, which it appears to have already achieved as of 2021. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...